Literature DB >> 23086639

[Cytotoxicity of homoharringtonine on leukemic stem-like cells in AML cell line KG-1].

Jian-ping Shen1, Hong Yang, Wan-mao Ni, Wen-bin Qian.   

Abstract

OBJECTIVE: To investigate the effect of homoharringtonine (HHT) on leukemic stem-like cells (LSC) in human acute myeloid leukemia (AML) cell lines.
METHODS: The phenotypes of AML cell lines U937,Kasumi-1,and KG-1 cells were analyzed by flow cytometry (FACS). The effect of HHT on leukemia stem-like cells with immunophenotype of CD34(+)CD38(-)CD96(+) was detected with FACS. Cell growth was measured by MTT assay. Activation of Caspase pathway and expression of apoptosis-related regulator proteins were examined by Western blotting.
RESULTS: FACS demonstrated that the 69% of KG-1 cells expressed LSC phenotype CD34(+)CD38(-)CD96(+), while 26.7% on Kasumi-1 cells expressed this marker. In contrast,U937 cells showed CD96 negative. HHT significantly inhibited cell growth of KG-1 cells with an IC(50) of 16.9 ng/ml at 48 h. The ratio of CD34(+)CD38(-)CD96(+) cells decreased from 63.6% to 17.1% after HHT treatment. Enhanced apoptosis was demonstrated in HHT group evidenced by strong activation of Caspase-9,Caspase-3 and PARP.HHT treatment resulted in down-regulation of expression of anti-apoptotic protein BCL-2 and phosphorylated-Akt.
CONCLUSION: HHT can effectively kill the leukemic stem-like cells in human AML cell line KG1 by inhibiting cell growth and inducing apoptosis which is associated with activation of Caspase pathway and down-regulation of anti-apoptotic proteins and phosphorylated-Akt.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23086639

Source DB:  PubMed          Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban        ISSN: 1008-9292


  6 in total

Review 1.  Homoharringtonine and omacetaxine for myeloid hematological malignancies.

Authors:  Shuqing Lü; Jianmin Wang
Journal:  J Hematol Oncol       Date:  2014-01-03       Impact factor: 17.388

2.  HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.

Authors:  Mixue Xie; Qi Jiang; Li Li; Jingjing Zhu; Lixia Zhu; Yanlong Zheng; Xiudi Yang; Mingyu Zhu; Jianai Sun; Wanzhuo Xie; Xiujin Ye
Journal:  PLoS One       Date:  2016-10-05       Impact factor: 3.240

3.  Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein.

Authors:  Jiang Cao; Hao Feng; Ning-Ning Ding; Qing-Yun Wu; Chong Chen; Ming-Shan Niu; Wei Chen; Ting-Ting Qiu; Hong-Hu Zhu; Kai-Lin Xu
Journal:  Cancer Med       Date:  2016-10-05       Impact factor: 4.452

4.  Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms.

Authors:  Fangfang Yuan; Dongbei Li; Gangping Li; Cheng Cheng; Xudong Wei
Journal:  Ann Transl Med       Date:  2022-04

5.  Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism.

Authors:  Fenglin Wang; Min Xie; Pan Chen; Dan Wang; Minghua Yang
Journal:  Oxid Med Cell Longev       Date:  2022-07-13       Impact factor: 7.310

6.  Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1.

Authors:  Noureldien H E Darwish; Thangirala Sudha; Kavitha Godugu; Osama Elbaz; Hasan A Abdelghaffar; Emad E A Hassan; Shaker A Mousa
Journal:  Oncotarget       Date:  2016-09-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.